Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093233 | 0.94 | — | — | |
| SCHEMBL7094165 | 0.92 | CACNA1F (0.31) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| SCHEMBL7095096 | 0.91 | — | — | |
| SCHEMBL7093340 | 0.91 | CACNA1F (0.33) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| SCHEMBL7093439 | 0.90 | CACNA1F (0.30) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| SCHEMBL7096796 | 0.89 | CACNA1F (0.30) | CACNA1FPOLBMAPK1CACNA1DKCNH2 | |
| SCHEMBL7093199 | 0.89 | — | — | |
| SCHEMBL7098275 | 0.89 | — | — | |
| SCHEMBL7093377 | 0.85 | — | — | |
| SCHEMBL7093483 | 0.85 | CACNA1F (0.33) | CACNA1FPOLBMAPK1CACNA1DKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | claimed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | CACNA1F 2279/4885POLB 3318/4885MAPK1 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.